Search Results - "Gillies, Steven D."

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma by Yu, Alice L, Gilman, Andrew L, Ozkaynak, M. Fevzi, London, Wendy B, Kreissman, Susan G, Chen, Helen X, Smith, Malcolm, Anderson, Barry, Villablanca, Judith G, Matthay, Katherine K, Shimada, Hiro, Grupp, Stephan A, Seeger, Robert, Reynolds, C. Patrick, Buxton, Allen, Reisfeld, Ralph A, Gillies, Steven D, Cohn, Susan L, Maris, John M, Sondel, Paul M

“…This study evaluated whether the addition of a monoclonal antibody against the tumor-associated disialoganglioside GD2, in combination with GM-CSF and…”
Get full text

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study by Shusterman, Suzanne, Naranjo, Arlene, Van Ryn, Collin, Hank, Jaquelyn A, Parisi, Marguerite T, Shulkin, Barry L, Servaes, Sabah, London, Wendy B, Shimada, Hiroyuki, Gan, Jacek, Gillies, Steven D, Maris, John M, Park, Julie R, Sondel, Paul M

“…Combining anti-GD2 (disialoganglioside) mAb with GM-CSF, IL2, and isotretinoin is now FDA-approved for high-risk neuroblastoma minimal residual disease (MRD)…”
Get full text

Use of Methotrexate-Based Peptide Substrates to Characterize the Substrate Specificity of Prostate-Specific Membrane Antigen (PSMA) by Mhaka, Annastasiah, Gady, Alyssa M., Rosen, D. Marc, Lo, Kin-Ming, Gillies, Steven D., Denmeade, Samuel R.

“…Prostate-Specific Membrane Antigen (PSMA) is a glutamate carboxypeptidase II that is highly expressed by both normal and malignant prostate epithelial cells…”
Get full text

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma by Goldberg, Jacob L, Navid, Fariba, Hank, Jacqueline A, Erbe, Amy K, Santana, Victor, Gan, Jacek, de Bie, Fenna, Javaid, Amal M, Hoefges, Anna, Merdler, Michael, Carmichael, Lakeesha, Kim, KyungMann, Bishop, Michael W, Meager, Michael M, Gillies, Steven D, Pandey, Janardan P, Sondel, Paul M

“…PurposePatients with cancer receiving tumor-reactive humanized monoclonal antibody (mAb) therapy can develop a human antihuman antibody (HAHA) response against…”
Get full text

Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: a Children’s Oncology Group phase II study by Shusterman, Suzanne, Naranjo, Arlene, Van Ryn, Collin, Hank, Jaquelyn A., Parisi, Marguerite T., Shulkin, Barry L., Servaes, Sabah, London, Wendy B., Shimada, Hiroyuki, Gan, Jacek, Gillies, Steven D., Maris, John M., Park, Julie R., Sondel, Paul M.

Get full text

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma by Yu, A L, Uttenreuther-Fischer, M M, Huang, C S, Tsui, C C, Gillies, S D, Reisfeld, R A, Kung, F H

“…To evaluate the toxicity, immunogenicity, and pharmacokinetics of a human-mouse chimeric monoclonal antibody (mAb) ch 14.18 directed against disialoganglioside…”
Get more information